Existing COVID-19 therapeutics present significant limitations for vulnerable populations including older adults and immunocompromised patients. Nirmatrelvir-ritonavir causes extensive drug-drug interactions through cytochrome P450 3A inhibition, while molnupiravir offers modest benefits with mutagenic concerns. Researchers have long sought an oral single-agent protease inhibitor without pharmacokinetic boosting requirements. In a prospective, multicentre cohort study published in the Journal of Thoracic Disease, Cheng and colleagues evaluated leritrelvir in 1,527 mild-to-moderate COVID-19 patients across 141 Chinese sites. The trial compared 1,388 participants receiving leritrelvir (400 mg three-times-daily for five days) plus standard care against 139 receiving standard care alone during Omicron EG.5 and JN.1 predominance. Using unadjusted analysis, multivariable regression, and propensity-score matching, leritrelvir-treated patients achieved sustained symptom resolution approximately two days earlier and SARS-CoV-2 negativity roughly one day earlier than controls. Effect directions remained consistent across analytical approaches. The findings represent a translational bridge between phase-three trial outcomes and real-world clinical conditions, though do not constitute definitive endorsement, supporting leritrelvir's potential as a ritonavir-free alternative meeting ongoing public health needs.

Long COVID patients frequently experience dysautonomia, a dysfunction of the autonomic nervous system that controls involuntary functions including heart rate, blood pressure, and temperature regulation. Postural orthostatic tachycardia syndrome (POTS), characterized by a sustained heart rate increase of 30 or more beats per minute within 10 minutes of standing, represents one form of dysautonomia present in Long COVID populations. Studies reveal varying prevalence rates depending on patient selection and testing methodology. A 100-patient cross-sectional study found POTS in 10 percent while 82 percent showed abnormal autonomic symptoms on the COMPASS-31 questionnaire. A larger 143-patient study identified POTS in 22 percent of cases, with 92 percent experiencing reduced brain blood flow when upright. A third study of 50 patients at a dedicated Long COVID clinic detected postural orthostatic tachycardia in 32 percent and postural orthostatic hypotension in 32 percent. These findings indicate dysautonomia is common in Long COVID and contributes significantly to symptom presentation, though precise prevalence rates remain unclear due to research setting bias. Comprehensive autonomic testing including heart rate, blood pressure, and cerebral blood flow measurements helps clinicians identify specific dysfunction mechanisms underlying post-COVID dizziness and related symptoms.

This open-access narrative review, published in the Journal of General Internal Medicine in October 2026, addresses the critical gap in primary care management of Long COVID. The article provides clinicians with practical, evidence-based approaches for evaluating and managing patients experiencing persistent symptoms following COVID-19 infection. Long COVID, characterized by prolonged debilitating symptoms affecting multiple organ systems, represents an increasingly significant burden on primary care systems globally. The review synthesizes current clinical evidence to guide primary care physicians in diagnostic evaluation, symptom assessment, and appropriate management strategies. By offering practical frameworks for Long COVID assessment in the primary care setting, this work enhances clinicians' capacity to identify affected patients early and implement targeted interventions. The timing and focus are particularly significant given the growing prevalence of Long COVID cases and the critical role primary care plays in managing chronic conditions, making this resource essential for improving patient outcomes and reducing unnecessary specialist referrals.

The COVID-19 pandemic exposed critical global vaccine inequities, with high-income countries achieving near-universal coverage by end-2021 while low-income nations vaccinated only four percent of their populations. Research modeling indicates that accelerating the global rollout by 100 days from viral sequencing could have prevented over 8 million deaths, predominantly in lower-middle-income countries, with an additional 3 million lives saveable through enhanced manufacturing and health system investments. Researchers Ghafari and colleagues have developed an "equity-by-design" framework addressing the complete vaccine-readiness pathway, encompassing financing, procurement, manufacturing, allocation, delivery, uptake, safety monitoring and accountability. The framework recommends six key actions: advance preparedness for future health emergencies, ensure equitable inter-nation vaccine allocation, secure timely and fair procurement mechanisms, foster transparent data sharing and communication, protect vaccination decisions from political interference, and reinforce delivery systems and regional capacity. The WHO Pandemic Agreement and revised International Health Regulations now provide institutional foundations for institutionalizing these equity-centered practices into standard pandemic preparedness protocols globally.

A target trial emulation study published in PLOS Global Public Health examined whether nirmatrelvir/ritonavir (Paxlovid, Pfizer) prevents long COVID in nonhospitalized adults. Researchers analyzed electronic health records from 497,499 patients across 29 PCORnet repositories participating in the NIH RECOVER Initiative, comparing 159,659 high-risk individuals treated with nirmatrelvir/ritonavir within five days of SARS-CoV-2 infection against 272,048 untreated controls, measured at 30 to 180 days post-infection. Early treatment demonstrated modest benefits for high-risk patients, reducing long COVID risk from 33.50 to 30.51 events per 100 individuals (HR 0.88), alongside decreased hospitalization (HR 0.70) and mortality (HR 0.53) risks. Benefits extended across multiple organ systems including neurological, pulmonary, and metabolic conditions. However, no clear long COVID reduction emerged among low-risk individuals without documented severe COVID risk factors. These findings advance understanding of Paxlovid's post-acute benefits in diverse populations, though results suggest treatment efficacy concentrates in higher-risk cohorts, addressing gaps in previous research limited to predominantly older, male veteran populations.

Paxlovid® (nirmatrelvir/ritonavir) is an antiviral combination therapy for treating symptomatic COVID-19 in high-risk adults who do not require supplemental oxygen. Nirmatrelvir functions as a peptidomimetic inhibitor of coronavirus 3C-like protease, while ritonavir inhibits CYP3A4-mediated metabolism to enhance nirmatrelvir efficacy. The treatment must be initiated within five days of symptom onset and administered for five days at a standard dose of three tablets taken twice daily (two 150mg nirmatrelvir tablets and one 100mg ritonavir tablet). Dose adjustments are necessary for patients with renal impairment; those with eGFR less than 30 require reduced dosing with pharmacy dispensing adjustments. Paxlovid® has significant drug-drug interactions involving CYP3A-dependent medications and potent inducers or inhibitors, requiring careful screening through resources including the BNF and product characteristics summary. Authorized prescribers include consultants across acute general medicine, infectious diseases, respiratory units, and critical care, with a mandatory BlueTeq form completion. This targeted approach addresses severe COVID-19 progression risk in vulnerable populations while requiring careful pharmacological management.

A new policy brief from the United Nations University Institute for Water, Environment and Health reveals that beginning the COVID-19 vaccine rollout 100 days after viral sequencing could have prevented over 8 million deaths by end-2021, predominantly in lower-middle-income countries. Developed collaboratively by researchers from UNU-INWEH, Oxford, Imperial College London, the London School of Hygiene and Tropical Medicine, and institutions across Japan, India, and the Middle East, the analysis demonstrates that parallel investment in manufacturing and health infrastructure could have saved an additional 3 million lives. The brief introduces an "equity-by-design" framework integrating vaccine development, financing, procurement, manufacturing, allocation, delivery, uptake, and safety monitoring. Proposing six practical recommendations aligned with the WHO Pandemic Agreement adopted in May 2025 and amended International Health Regulations, the research emphasizes establishing fair vaccine-sharing protocols before future pandemics rather than negotiating during crises. While COVID-19 vaccines achieved faster and more equitable distribution than previous vaccines, significant inequality persisted, highlighting the critical importance of proactive international commitment to health equity.

This article examines the glymphatic and meningeal lymphatic systems and their roles in protein homeostasis, autophagy, and various disease mechanisms. The glymphatic system facilitates cerebrospinal fluid circulation through the brain to clear metabolic waste, while the meningeal lymphatic system drains fluid and solutes from the central nervous system. The document explores how autophagy—the cellular process of protein degradation and recycling—connects to circadian rhythms and sleep dysfunction, fatigue, and post-exertional malaise (PEM). It identifies multiple sources of pathogenic protein aggregates, including misfolded proteins, cell debris, senescent cells, and intracellular pathogens, alongside contributions from gut microbiome dysregulation, axonal damage, oxidative stress, and fibrinogen-resistant microclots. The article details how metabolic dysregulation and impaired autophagy mechanisms contribute to disease pathology. Understanding these interconnected systems is critical for comprehending neurological and systemic diseases, particularly conditions involving protein misfolding, neuroinflammation, and post-infectious complications where glymphatic clearance dysfunction may play a central pathogenic role.

COVID-19 has demonstrated a significant association with thrombotic complications in severe cases, with over 70% of fatal cases exhibiting coagulopathy. This review examines the role of the von Willebrand factor (VWF) and ADAMTS13 axis in COVID-19-associated thrombosis. While SARS-CoV-2 infection primarily affects the respiratory system, it triggers widespread microvascular thrombosis through inflammatory endothelial injury and hypercoagulability. Unlike other acute infections, COVID-19-associated coagulopathy manifests early in disease progression. The VWF/ADAMTS13 balance is critical for maintaining vascular health and organ perfusion. Researchers from institutions including the University of Kansas Medical Center and Chinese medical centers are investigating novel therapeutic approaches beyond standard anticoagulation. Emerging treatments under study include recombinant ADAMTS13 and Caplacizumab, an anti-VWF nanobody, which demonstrate high efficacy in vitro against thrombosis. This review synthesizes current research on correcting the VWF-ADAMTS13 imbalance to treat COVID-19-associated coagulopathy, addressing existing challenges and future therapeutic prospects in managing this critical complication.

An international research team led by investigators from IrsiCaixa and affiliated Spanish institutions conducted a cross-sectional analysis of 312 individuals—including 139 people with long COVID and 99 recovered COVID-19 controls—to investigate the biological mechanisms underlying persistent post-COVID symptoms. The study examined immune dysregulation, endothelial dysfunction, and SARS-CoV-2 component persistence as potential drivers of long COVID. The researchers identified significant dysregulation of the IL-1 (interleukin-1) pathway as a key finding in long COVID patients, without detecting persistent viral components. This discovery is critical because it suggests long COVID involves specific inflammatory pathway abnormalities rather than ongoing viral infection, potentially opening new therapeutic avenues. The IL-1 pathway dysregulation represents a distinct biological mechanism that could explain the persistent, often disabling symptoms characteristic of long COVID. Understanding whether this pathway abnormality represents a distinct biological subtype or overlaps with other proposed mechanisms—such as endothelial dysfunction—has important implications for developing targeted treatments. These findings advance the biological characterization of long COVID and may help identify patients who could benefit from IL-1-targeted interventions.

Researchers Manful, Subramaniam, Fordjour, Abbey, and Thomas have published a comprehensive review in Frontiers in Immunology examining monoacetyldiacylglycerols (MAGs) as emerging immunomodulatory lipid mediators in chronic inflammation. The study explores the mechanisms through which MAGs regulate immune responses, focusing on their roles in macrophage polarization and neutrophil function. Key signaling pathways investigated include the NF-κB pathway and STAT3/STAT6 signaling cascades, which are critical regulators of inflammatory and anti-inflammatory responses. The research addresses how MAGs can modulate these pathways to suppress chronic inflammatory states. By elucidating the biological mechanisms underlying MAG immunomodulation, this work establishes the translational potential of these lipid molecules as therapeutic targets. The findings suggest that MAGs represent a promising avenue for developing novel treatments for chronic inflammatory diseases, offering an alternative approach to existing immunomodulatory strategies. This research bridges fundamental lipid biology with clinical applications, positioning MAGs as candidates for future drug development.

A real-time meta-analysis of 20 studies examining tixagevimab/cilgavimab, a monoclonal antibody treatment for COVID-19, reveals a 29% reduction in overall risk across the most serious reported outcomes, with particularly strong benefits for hospitalization (63% improvement) and cases (64% improvement). Data from nine independent teams across three countries demonstrated significant efficacy, with mortality reduced by 32% and ICU admissions by 53%. However, efficacy varies considerably by variant, with in vitro research indicating diminished effectiveness against multiple Omicron subvariants including BA.2.75, BA.4.6, BQ.1.1, and XBB lineages. The U.S. Emergency Use Authorization for this treatment has been revoked. The analysis highlights emerging concerns including potential variant emergence, autoimmune disease associations, prolonged viral loads, and increased cardiac event risks. While results remain statistically significant in peer-reviewed studies, sensitivity analysis shows significance loss after excluding just two studies, suggesting moderate robustness. The findings underscore that monoclonal antibody treatments should be combined with alternative therapies and individualized risk-benefit assessments rather than used as standalone interventions.

Dr. Alina Fong, a clinical neuropsychologist and Co-Founder of Cognitive FX, brings extensive expertise to understanding Long COVID fatigue. With a Ph.D. in Clinical Neuropsychology from Brigham Young University and over 17 years of clinical experience, Dr. Fong has developed the EPIC Treatment protocol and overseen care for nearly 8,000 brain injury patients, including elite athletes from the NFL, NHL, and Olympics. Her research focuses on functional MRI applications in concussion treatment and brain injury rehabilitation. As Vice President of the Brain Injury Alliance of Utah and board member of the United States Brain Injury Alliance, Dr. Fong bridges clinical practice with research, having authored peer-reviewed publications and presented findings at over 60 medical conferences, including the Federal Interagency Conference on TBI. Her work addresses the neurobiological mechanisms underlying post-infectious fatigue, connecting Long COVID symptoms to brain injury pathophysiology and establishing evidence-based treatment approaches for this emerging condition affecting millions globally.

Researcher Keiko Kubo from the HSG Interstitial Research Lab in Japan proposes a novel framework linking persistent Long COVID symptoms to both intravascular and extravascular pathology. While Long COVID is known to involve endothelial dysfunction, microvascular impairment, and coagulation abnormalities, Kubo argues that vascular injury may also generate chronic extravascular damage. She introduces chronic intra- and extravascular coagulation (CIEC) as a continuous pathological mechanism wherein COVID-associated immunothrombosis triggers vascular leakage, local fibrin formation, and incomplete resolution of fibrin-containing provisional matrices in tissue spaces. Complementing this, Kubo presents the dual-axis microvascular-interstitial model (DMIM), which describes how abnormalities on both sides of the vascular wall interact functionally. The model proposes that impaired microvascular tissue supply and abnormal interstitial mechanics together contribute to tissue dysfunction and symptoms. This integrative framework connects established microvascular findings with the proposed extravascular component and generates testable predictions for future histological, biochemical, molecular imaging, and biomechanical investigations. The approach acknowledges Long COVID's heterogeneous nature while offering a comprehensive mechanistic pathway for understanding how vascular, coagulation, immunological, and metabolic abnormalities interact.

During the COVID-19 pandemic, Miami-Dade County experienced significant health disparities, with Black residents facing disproportionately high mortality rates compared to White residents. Researchers at the University of Miami leveraged an established Community Health Worker (CHW) network originally designed for HIV outreach to address these emerging COVID-19 disparities. Over a two-year period from June 2021 through May 2023, the CHW coalition, built on a decade-long partnership with nine community-based organizations, integrated COVID-19 education and vaccination support into existing protocols. The intervention reached over 400,000 residents with education on COVID-19 risk factors and vaccine safety, screened 8,672 individuals for COVID-19, and successfully referred 5,341 people for vaccination. The findings demonstrate that trusted community health workers are uniquely effective at bridging healthcare access gaps in vulnerable populations during public health emergencies. By adapting an established HIV-focused infrastructure, the researchers showed that community-led interventions can efficiently scale up to address urgent health threats while maintaining alignment with community values and overcoming historical barriers to care.

This real-time meta-analysis from October 2026 examines the efficacy of ensitrelvir, an antiviral treatment for COVID-19, across ten studies conducted by nine independent research teams, all from the same country. The analysis reveals that ensitrelvir reduces overall risk by twelve percent compared to controls, with more pronounced benefits for specific outcomes including a sixty-eight percent reduction in cases and thirty-six percent improvement in viral clearance. Notably, early treatment administration proved significantly more effective than late-stage intervention, while randomized controlled trials demonstrated fourteen percent risk reduction compared to nine percent in peer-reviewed studies. However, critical limitations persist: the evidence base remains modest with only seventeen control events reported for the primary outcome, and emerging viral variants may exhibit resistance to ensitrelvir. The analysis emphasizes that early intervention combined with comprehensive risk-benefit assessment and monitoring represents optimal clinical practice, though the authors acknowledge that alternative treatments demonstrate superior efficacy in certain contexts.

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating condition characterized by persistent, severe fatigue unrelieved by rest, often accompanied by cognitive difficulties, post-exertional malaise, and systemic dysfunction. Despite its significant impact on daily functioning, ME/CFS remains poorly understood and frequently misdiagnosed, as sufferers often appear outwardly healthy while routine medical tests reveal no clear abnormalities. The condition's etiology remains unclear, though it may be triggered by viral infections or immune stress; no curative treatment currently exists. Recognizing this medical need, stem cell-based therapy is emerging as a promising therapeutic approach. Rather than offering a direct cure, this regenerative medicine strategy aims to support the body's natural repair and regulatory mechanisms to address the underlying pathophysiology. This article examines how stem cell therapy functions in treating ME/CFS and identifies patient populations most likely to benefit from this innovative approach, offering new hope for millions suffering from this chronic, multi-system condition.

Long COVID presents significant clinical heterogeneity, with identical symptoms frequently stemming from disparate physiological mechanisms including autonomic dysfunction, mitochondrial impairment, endothelial dysfunction, mast cell activation, gut dysbiosis, and neuroendocrine dysregulation. Traditional symptom-based classification proves insufficient for identifying dominant mechanisms or directing treatment. Robert Groysman proposes the trigger-timing framework, a clinically accessible method that interprets patient-reported symptom behavior through a mechanistic lens. The framework leverages common daily stressors—upright posture, temperature exposure, physical or cognitive exertion, meals, emotional stress, sleep disruption, alcohol, and intercurrent illness—as physiologic probes. By analyzing four core dimensions (trigger, timing, symptom pattern, and recovery), clinicians can differentiate response kinetics and infer underlying mechanisms. Immediate worsening with standing or heat suggests autonomic dysfunction, delayed worsening after exertion indicates impaired recovery physiology, meal-related symptoms point to autonomic or metabolic pathology, and circadian patterns suggest neuroendocrine dysregulation. This framework complements mechanism-anchored network models and facilitates targeted diagnostic evaluation, treatment prioritization, and research cohort enrichment in Long COVID management.

Health Canada has authorized Pfizer and BioNTech's XFG variant-adapted COMIRNATY vaccine for individuals aged six months and older, effective for the 2026-2027 COVID-19 season. The updated formulation targets the Omicron XFG lineage in alignment with public health recommendations to better match currently circulating variants. The authorization relies on cumulative clinical, non-clinical, and real-world evidence demonstrating the vaccine's safety and effectiveness. Built on BioNTech's proprietary mRNA technology, COMIRNATY represents the companies' ongoing commitment to evolving vaccine formulations as the virus mutates. Pfizer Canada has secured sufficient inventory to meet all contractual obligations with federal and provincial vaccination programs, with distribution beginning through various channels in the coming weeks. This approval highlights vaccination's continued importance as an effective tool for reducing serious COVID-19 illness risk amid ongoing viral evolution.

Long COVID, clinically termed post-acute sequelae of COVID-19 (PASC), is a multisystem condition characterized by persistent symptoms lasting more than three months after acute infection that cannot be attributed to alternative diagnoses. Affected individuals commonly experience fatigue, brain fog, muscle pain, breathlessness, post-exertional malaise, dizziness, and cardiac symptoms indicative of autonomic dysfunction. Data from Welltory reveals that users self-reporting Long COVID experience post-exertion crashes 2.6 times more frequently and wake unrefreshed 4.6 times more often than other users, despite comparable daily wellness scores. Notably, no single diagnostic test definitively confirms Long COVID; diagnosis relies on clinical symptomatology and timeline. Globally, an estimated 400 million individuals experience persistent Long COVID symptoms following SARS-CoV-2 infection. Researchers acknowledge that underlying pathological mechanisms remain incompletely understood, though the disease's heterogeneity suggests a multifactorial origin. This distinction from typical post-infection malaise underscores Long COVID's significant impact on physiological regulation systems including energy, cognition, respiration, cardiac function, sleep, and activity tolerance.